The Unicorn Foundation New Zealand has been verbally advised of the outcome of the recent Pharmac Pharmacology and Therapeutics Advisory Committee (PTAC) committee. They have agreed with the recommendation to fund PRRT for NET cancer patients in New Zealand!
This is a hugely positive step forward, however there is still more work to be done to get the funding over the line. Unicorn Foundation New Zealand will spend the next few months working with Pharmac and NET clinicians to outline all the infrastructure needed to be able to deliver PRRT in New Zealand. Once all the information has been gathered, it will be ranked against all other treatments that Pharmac is considering for funding – hopefully PRRT will make it to the top of the list and we will do everything we can to help.

“Thank you to every single person who has helped, whether you have fundraised for us, donated, or signed petition letters or just following our social media, every bit really does make a difference. This has been many years of work to get to this point and we are so grateful to every single one of you in our Unicorn community.”, said Unicorn Foundation New Zealand CEO Siobhan Conroy.